HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(®) observational database: a cohort study

BACKGROUND: HLA-B*57:01 screening was added to clinical care guidelines in 2008 to reduce the risk of hypersensitivity reaction from abacavir. The uptake of HLA-B*57:01 screening and incidence of hypersensitivity reaction were assessed in a prospective clinical cohort in the United States to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mounzer, Karam, Hsu, Ricky, Fusco, Jennifer S., Brunet, Laurence, Henegar, Cassidy E., Vannappagari, Vani, Stainsby, Chris M., Shaefer, Mark S., Ragone, Leigh, Fusco, Gregory P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334426/
https://www.ncbi.nlm.nih.gov/pubmed/30651100
http://dx.doi.org/10.1186/s12981-019-0217-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334426/
https://www.ncbi.nlm.nih.gov/pubmed/30651100
http://dx.doi.org/10.1186/s12981-019-0217-3

Ejemplares similares